Clinical Trial Update: 1/2-Dopaminergic Dysfunction in Late-Life Depression (The D3 Study) [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update on 1/2-dopaminergic dysfunction in late-life depression (The D3 Study) has terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cognitive Impairment
• Gait Impairment
• Major Depressive Disorder

Snippet

Sponsor: New York State Psychiatric Institute | Conditions: Depression, Cognitive Impairment | Phase 4 | Status: TERMINATED | Results posted: 2023-05-22